DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Georgia Universities Join NIH-funded National Study of Bone Marrow Transplant for SCD
The Medical College of Georgia (MCG) and Augusta University Health (AU Health) have joined the first large, national clinical trial investigating bone marrow transplantation as part of the standard of care (SoC) for patients with sickle cell disease (SCD).
The National Institutes of Health (NIH)-funded study will conduct bone marrow transplants in patients who have high-risk SCD and who have a compatible bone marrow donor (typically a sibling, but it also can be an unrelated donor), and follow patients for whom a compatible donor wasn’t found, while giving them SoC treatment.


Related Content
-
news & events1st Patients to Get CRISPR Gene-Editing Treatment Continue to ThriveThe last thing a lot of people want to d...
-
videos & visualsAdvances in the Treatment of Sickle Cell Disease: L-Glutamine, Crizanlizumab & Gene Therapyhttps://www.youtube.com/watch?v=wkm4axJ3...
-
education & researchHydroxyureaHydroxyurea (Hydrea) is used alone or wi...
-
education & researchHydroxyurea: A Treatment Option for Sickle Cell DiseaseHydroxyurea is a chemotherapy drug used ...
-
Community CenterSuccessful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
-
news & eventsASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease TherapiesThe American Society of Hematology (ASH)...
-
news & eventsGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSM...Global Blood Therapeutics, Inc. (GBT) (N...
send a message
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.